First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Purpose: The purpose of this study is to evaluate the pharmacokinetics, immunogenicity, safety, and tolerability of guselkumab, a human monoclonal antibody with high affinity and specificity for binding to interleukin-23. Methods: In this first-in-human, phase 1, randomized study, a single intraveno...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 72; no. 11; pp. 1303 - 1311 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Springer Nature
Nov2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |